Digital PCR (dPCR) and qPCR Market worth 4.94 Bn USD by 2021

Tuesday 12 April 2016, Amsterdam

The report, now available on ASDReports, "Digital PCR (dPCR) and qPCR Market by Technology (Quantitative, Digital), Product (Instrument, Reagent, Software), Application (Clinical, Research, Forensic), End User (Hospital, Diagnostic Center, Academia, Pharma-Biotech Co) - Global Forecasts to 2021", analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

The global qPCR and dPCR market is expected to reach USD 4.94 Billion by 2021 from USD 3.28 Billion in 2016, growing at a CAGR of 8.5% from 2016 to 2021.

On the basis of technology, the qPCR and dPCR market is categorized into digital PCR (dPCR) and quantitative PCR (qPCR). The qPCR technology segment is expected to account for the larger share of the global qPCR and dPCR market in 2016; whereas, the dPCR segment is expected to grow faster as compared to qPCR during the forecast period. Factors such as ongoing technological developments in dPCR, continued expansion in distribution networks of emerging dPCR product manufacturers in global markets (the U.S., Europe, Asia-Pacific, and the Middle East), and growing private funding to develop and commercialize innovative dPCR instruments are contributing to the growth of this market segment.

On the basis of application, the qPCR and dPCR market is categorized into clinical applications, research applications, and forensic applications. The clinical applications segment is expected to grow at the highest CAGR in the dPCR market owing to the technological benefits offered by dPCR over qPCR and traditional PCR, growing adoption of dPCR among hospitals and diagnostic centers, increasing global burden for cancer and AIDS, and expansion in distribution networks of emerging dPCR product manufacturers.

Factors such as rising incidences of infectious diseases and genetic disorders (coupled with growing geriatric population that is at greater risk of target diseases as compared to adults); technological advancements; increasing public–private investments, funds, and grants; successful completion of the Human Genome Project; and growth in the number of hospitals and diagnostic centers are driving the qPCR and dPCR market.

North America is expected to account for the largest share of the global qPCR and dPCR market in 2016, followed by Europe. The strong position of North America in the qPCR and dPCR market can be attributed to factors such as increase in public and private funding and growing number of research grants to support gene-based research (such as qPCR and dPCR). However, Asia-Pacific (comprising China, India, Japan, and the Rest of Asia-Pacific) is projected to be the fastest-growing region in the qPCR and dPCR market owing to increasing focus of global life sciences market players on this region, burgeoning efforts to increase awareness related to gene-based disease diagnosis and treatment, growing public and private support to develop novel qPCR and dPCR technologies, growth in the Indian genomics market, and growing cancer research in Japan. Due to the significant growth opportunities offered by emerging countries, a number of players operating in the market are focusing on expanding their product distribution networks across emerging countries.

Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (The Netherlands), Agilent Technologies, Inc. (U.S.), BioMerieux S.A. (France), Fluidigm Corporation (U.S.), Takara Bio Inc. (Japan), Affymetrix Inc. (U.S.), and RainDance Technologies, Inc. (U.S.) were some of the key players in the global qPCR and dPCR market in 2015.